Ranbaxy in licensing pact with Gilead Sciences for HIV drug

Our Bureau New Delhi | Updated on August 03, 2012 Published on August 03, 2012

Pharma major Ranbaxy Laboratories Ltd on Friday entered into an in-licensing agreement with Gilead Sciences to promote access to low-cost generic versions of Gilead’s HIV medicine emtricitabine in developing countries.

Gilead will provide a technology transfer for the manufacture of emtricitabine, together with funding to assist with investment in process improvements to reduce manufacturing costs, Ranbaxy said in a filing to the Bombay Stock Exchange.

“The association with Gilead will enable us to offer quality, affordable medicines for treatment of HIV/ AIDS in the developing countries,” Arun Sawhney, Chief Executive Officer and Managing Director, Ranbaxy said.

The company would sell single tablet regimens containing emtricitabine, and fixed-dose combinations of emtricitabine co-formulated with other Gilead HIV medicines.

Published on August 03, 2012
This article is closed for comments.
Please Email the Editor